Back to discover

Protein / target

Protein kinase C iota type

Encoded byPRKCIP41743Homo sapiensSwiss-Prot
Clinically validated
Therapeutic maturity
1
Approved medicines
Open Targets target-level
View by indication →
30
Clinical trials
Small-molecule tractable
Druggability
Approved Drug

Protein at a glance

Biological role

Protein serine/threonine kinase

Strongest disease association

Prostate carcinoma

Via encoding gene PRKCI · Genetic evidence · score 0.67

Therapeutic position

Established drug target

Small molecules

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Calcium- and diacylglycerol-independent serine/ threonine-protein kinase that plays a general protective role against apoptotic stimuli, is involved in NF-kappa-B activation, cell survival, differentiation and polarity, and contributes to the regulation of microtubule dynamics in the early secretory…

View complete UniProt function annotation

Calcium- and diacylglycerol-independent serine/ threonine-protein kinase that plays a general protective role against apoptotic stimuli, is involved in NF-kappa-B activation, cell survival, differentiation and polarity, and contributes to the regulation of microtubule dynamics in the early secretory pathway. Is necessary for BCR-ABL oncogene-mediated resistance to apoptotic drug in leukemia cells, protecting leukemia cells against drug-induced apoptosis. In cultured neurons, prevents amyloid beta protein-induced apoptosis by interrupting cell death process at a very early step. In glioblastoma cells, may function downstream of phosphatidylinositol 3-kinase (PI(3)K) and PDPK1 in the promotion of cell survival by phosphorylating and inhibiting the pro-apoptotic factor BAD. Can form a protein complex in non-small cell lung cancer (NSCLC) cells with PARD6A and ECT2 and regulate ECT2 oncogenic activity by phosphorylation, which in turn promotes transformed growth and invasion. In response to nerve growth factor (NGF), acts downstream of SRC to phosphorylate and activate IRAK1, allowing the subsequent activation of NF-kappa-B and neuronal cell survival. Functions in the organization of the apical domain in epithelial cells by phosphorylating EZR. This step is crucial for activation and normal distribution of EZR at the early stages of intestinal epithelial cell differentiation. Forms a protein complex with LLGL1 and PARD6B independently of PARD3 to regulate epithelial cell polarity. Plays a role in microtubule dynamics in the early secretory pathway through interaction with RAB2A and GAPDH and recruitment to vesicular tubular clusters (VTCs). In human coronary artery endothelial cells (HCAEC), is activated by saturated fatty acids and mediates lipid-induced apoptosis. Involved in early synaptic long term potentiation phase in CA1 hippocampal cells and short term memory formation (By similarity)

Subcellular location

CytoplasmMembraneEndosomeNucleus
Domains and Gene Ontology detail (52)

Domains & features

PB1Protein kinaseAGC-kinase C-terminal

Gene Ontology

  • Capical plasma membrane
  • Cbicellular tight junction
  • Cbrush border
  • Ccell leading edge
  • Ccilium
  • Ccytosol
  • Cendosome
  • Cextracellular exosome
  • Cglutamatergic synapse
  • CGolgi membrane
  • Cnucleoplasm
  • Cnucleus

596 aa · 68 kDa

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Lipid & lipoprotein metabolismUniProt · GOSynaptic signallingGOCell proliferation & survivalUniProtCell migrationGOOncogenic signallingUniProtKinase signallingUniProt · GO
View supporting evidence

Lipid & lipoprotein metabolism

  • ·Calcium- and diacylglycerol-independent serine/ threonine-protein kinase that plays a ge…
  • ·phospholipid binding

Synaptic signalling

  • ·glutamatergic synapse
  • ·Schaffer collateral - CA1 synapse
  • ·regulation of postsynaptic membrane neurotransmitter receptor levels

Cell proliferation & survival

  • ·Calcium- and diacylglycerol-independent serine/ threonine-protein kinase that plays a ge…

Cell migration

  • ·cell migration

Oncogenic signalling

  • ·Calcium- and diacylglycerol-independent serine/ threonine-protein kinase that plays a ge…

Kinase signalling

  • ·Calcium- and diacylglycerol-independent serine/ threonine-protein kinase that plays a ge…
  • ·diacylglycerol-dependent, calcium-independent serine/threonine kinase activity
  • ·protein kinase activity
  • ·protein serine kinase activity

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Approved medicines with mapped indications

1 medicine · 4 areas

Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.

Leukemia, Myeloid, Acute1 medicine
Mastocytosis1 medicine
Mastocytosis, Systemic1 medicine
Broader indication categories (1)
Neoplasms1 medicine

Broad umbrella indications (e.g. “Neoplasms”). Shown here because every medicine also appears under a more specific disease above — kept for completeness, de-emphasised for clarity.

Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.

Drugs targeting this protein

1

How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.

midostaurin
ApprovedInhibitor

Protein kinase C (PKC) inhibitor

Indicated for Leukemia, Myeloid, Acute, Mastocytosis, Mastocytosis, Systemic, Neoplasms

Acts on a complex — shared with PRKD3, PRKCA, PRKCG +7 more · 1 of 16 recorded protein targets — broad pharmacology

ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene PRKCI

Gene-level evidence surfaced through the gene PRKCI that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Prostate carcinoma
0.69Moderately supported

Genetic evidence dominant · Open Targets 0.42

Neoplasms
0.54Moderately supported

Clinical evidence dominant · Open Targets 0.41

Alzheimer's Disease
0.14Preliminary

Pathway evidence dominant · Open Targets 0.20 · no direct causal or clinical evidence

View evidence synthesis (3)
Prostate carcinomaModerately supported
0.69
agreement 0.550.83
Genetic94%Literature6%

Open Targets aggregate 0.42 · 2 independent evidence families

NeoplasmsModerately supported
0.54
agreement 0.390.70
Clinical77%Literature23%

Open Targets aggregate 0.41 · 2 independent evidence families

Alzheimer's DiseasePreliminary
0.14
agreement 0.000.32
Pathway91%Literature10%

Open Targets aggregate 0.20 · 2 independent evidence families · no direct causal or clinical evidence

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Prostate carcinoma0.42
Neoplasms0.41
Alzheimer's Disease0.20

Drug development

5 compounds recorded · 1 approved · 4 in clinical development

Open Targets' development universe — every compound recorded against the target at any stage, not all approved medicines. Distinct from the 1 drug that targets this protein in Forefront's canonical graph (1 with a mapped approved indication, shown above): these count different sets and are not a subset relation.

View all recorded compounds (5)
SOTRASTAURINPhase 2
MIDOSTAURINApproval
UCN-01Phase 2
CEP-2563Phase 1
GSK-690693Phase 1

Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.

Tractability

Small moleculesStrong

Approved Drug and Structure with Ligand support this modality.

AntibodiesEmerging

Feasibility evidence (go cc high conf) — no clinical-stage drug of this modality recorded.

Protein degradersEmerging

Feasibility evidence (literature and database ubiquitination) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (10)
SM · Approved DrugSM · Structure with LigandSM · High-Quality LigandSM · High-Quality PocketSM · Druggable FamilyAB · GO CC high confPR · LiteraturePR · Database UbiquitinationPR · Half-life DataPR · Small Molecule Binder

Raw Open Targets tractability assessment buckets, by modality.

Clinical trials

30

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.

View all trials (26)

ClinicalTrials.gov via the drug-target graph.

What's happening now

3

Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for a drug that targets this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.

  1. Regulatory approval2017-09-18

    Approval: Rydapt (EMA)

    ema · regulatory · ema · via midostaurin

  2. New publication2017-07-24
    Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial.

    Leukemia · 2018 · 109 citations · Europe PMC · via midostaurin

  3. New publication2016-06-01
    Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis.

    The New England journal of medicine · 2016 · 371 citations · Europe PMC · via midostaurin

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.